Acumen Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Acumen Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
Acumen Pharmaceuticals, Inc. Announces Topline Results From Phase 2 ALTITUDE-AD Clinical Trial Of Sabirnetug For The Treatment Of Early Alzheimer?s Disease
The story matters when it changes Acumen Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Acumen Pharmaceuticals, Inc. reports third quarter 2026 financial results and targets November 2026 for ALTITUDE-AD topline results
The story matters when it changes Acumen Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
The story matters when it changes Acumen Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Investors are testing whether Acumen Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Acumen Pharmaceuticals, Inc. to Present Research on Sabirnetug for Alzheimer's Disease at International Conferences in April 2025
The story matters when it changes Acumen Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
The story matters when it changes Acumen Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest ABOS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Acumen Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →